What question did this study set out to answer?

To evaluate the efficacy and safety of JNJ-95437446, an EGFR/MET bispecific antibody drug conjugate.

April 19, 2026

Abstract LB473: JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications

Key Points

To evaluate the efficacy and safety of JNJ-95437446, an EGFR/MET bispecific antibody drug conjugate.
Evaluated JNJ-95437446 in preclinical models of solid tumors including NSCLC, colorectal, and head & neck carcinomas.
Assessed pharmacokinetic properties and stability of linker/payload in multiple tests.
Conducted safety assessments in GLP NHP studies across various doses.
Demonstrated potent, target-dependent cytotoxicity in vitro with rapid internalization.
Achieved complete tumor regressions in NSCLC xenograft models resistant to amivantamab.
Showed favorable safety profile with strong tolerability in GLP NHP studies.

Abstract

Abstract JNJ-95437446 is a potential best-in-class EGFR/MET bispecific antibody drug conjugate designed to deliver a cytotoxic payload to tumor cells while leveraging the unique characteristics of amivantamab. EGFR and MET are frequently expressed in solid tumors and amivantamab has demonstrated clinical efficacy in multiple non-small cell lung cancer (NSCLC) indications and is being studied in colorectal and head Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr LB473.

Abstract LB473: JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications

Key Points

Abstract

Cite This Study